Inomagen
Chicago, US · Founded 2014 · 1 known investors
Inomagen Therapeutics develops a non-viral gene therapy delivered via a single-dose, minimally invasive procedure to target the underlying mechanisms of atrial fibrillation. The company operates under an exclusive license from Northwestern University and is based in a biotech incubator in Chicago.
BiotechHealthtechMedical Devices
Founders & leadership
Inomagen was founded in 2014 by Rishi Arora.
RA
Rishi AroraFounder
GA
Gerard AbateChief Medical Officer
ES
Eric SandbergChief Business Officer
Board
MP
Marc PennBoard director
JR
James R. VoglerBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$540K disclosed across 3 rounds · 2014–2025
▶$140KraisedJun 2025 · 4 investors · BiotechnologyRule 506(c)
▶$140KraisedJun 2025 · 4 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Rishi AroraExecutive Officer, Director
- Marc PennDirector
- James R. VoglerDirector
- Offering amount
- $3.8M
- Amount sold
- $140K
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$200KraisedApr 2024 · 4 investors · BiotechnologyRule 506(b)
▶$200KraisedApr 2024 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rishi AroraExecutive Officer, Director
- James R. VoglerDirector
- Marc PennDirector
- Offering amount
- $6.6M
- Amount sold
- $200K
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$200KraisedNov 2014 · 8 investors · BiotechnologyRule 506(b)
▶$200KraisedNov 2014 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rishi AroraExecutive Officer, Director
- Offering amount
- $400K
- Amount sold
- $200K
- Minimum investment
- $25K
- First sale
- Nov 2014
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapBiogen Idec10 shared keywordsBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
Regeneron NASDAQ: REGN www.regeneron.com8 shared keywordsRegeneron is a biopharmaceutical company that develops medicines ranging from biologics to genetic medicines for people with serious diseases across areas such as metabolic disease, ophthalmology, and rare diseases. It runs research and development programs and clinical trials aimed at treating conditions including generalized myasthenia gravis.
Orogentx6 shared keywordsOrogen Therapeutics is a drug discovery company that uses AI-enabled DNA-encoded library (DEL) technology and machine learning to identify novel small-molecule compounds targeting cytokine-related immuno-inflammatory disorders. The company focuses on developing oral small-molecule candidates for therapeutic areas including dermatology, rheumatology, and gastroenterology.
Companies competing with Inomagen for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Inomagen do?
- Inomagen Therapeutics develops a non-viral gene therapy delivered via a single-dose, minimally invasive procedure to target the underlying mechanisms of atrial fibrillation. The company operates under an exclusive license from Northwestern University and is based in a biotech incubator in Chicago.
- Who founded Inomagen?
- Inomagen was founded by Rishi Arora in 2014.
- Who are Inomagen's investors?
- Inomagen's investors include Portal Innovations.
- How much funding has Inomagen raised?
- Inomagen has disclosed $540K raised across 3 rounds.
- Where is Inomagen headquartered?
- Inomagen is headquartered in Chicago, US.